… Vascular Endothelial Growth Factor-A (VEGF-A) is … disease (PAD) [Citation19], this review
focuses on the recent advances in our understanding of the ‘anti-angiogenic’ VEGF-A isoforms …

… between proangiogenic and anti-angiogenic factors [Citation9]… factors such as vascular
endothelial growth factor (VEGF) and … There are three common isoforms of NOS: neuronal nitric …

… Currently, there are two studies showing that VEGFAx has anti-angiogenic [77] or pro-…
pro-angiogenic vascular endothelial growth factor A (VEGFA) therapy to treat patients with different …

… antibody (mAb), anti-vascular endothelial growth factor-A (VEGF-A), … in renal failure, arthritis,
psoriasis and coronary disease [69–72]. … VEGF induces NFATc1, one of the NFAT isoforms, …

… Although the VEGF isoforms are known for their pro-angiogenic effects, inhibitory isoforms
… In 2014, a novel anti-angiogenic VEGF isoform was described, VEGFAx, with a 22-amino …

… The well characterized heparin-binding isoform, VEGF165, is … Anti-VEGF treatment as
anti-angiogenic therapy in cancer is … Patients with serious co-morbidity (eg end-stage renal failure, …

… promise, we examine the structural basis for anti-angiogenic therapy using small-molecule …
Thus, VEGF-E isoforms have the potential to be candidates for selectively targeting VEGFR2…

… Vascular endothelial growth factor‐A (VEGF‐A) mediates angiogenesis and is upregulated
in the plaques and plasma of patients with … have significant anti‐angiogenic properties and …

… anti-angiogenic antibody approved for the treatment of colorectal cancer (CRC), and then
approved in various diseases such … directed towards all VEGF-A isoforms [75]. This antibody is …

… Assessment of the levels of vascular endothelial growth factor, … vascular stiffness indices in
chronic kidney disease. Material and methods. 261 patient with chronic kidney disease (CKD) …